Stockreport

Dr. Seth Forman to Chair XBiotech’s Second Phase 2 Study of Bermekimab in Atopic Dermatitis

XBiotech Inc.  (XBIT) 
Last xbiotech inc. earnings: 8/9 03:01 pm Check Earnings Report
US:NASDAQ Investor Relations: xbiotech.com/about/investors.html
PDF AUSTIN, Texas, July 11, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announces that Seth Forman, M.D., will Chair the Company’s upcoming randomized, double-blind, [Read more]